A Phase 3 COVID-19 Vaccine Study
A Randomized, Double-blind, Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
Funder: Janssen-Cilag Ltd
Sponsor: Janssen-Cilag Ltd
CI: Professor Saul Faust
Approval Date: 28 August 2020
The aim of this study is to evaluate the efficacy, safety, and immunogenicity of Ad26.COV2.S in participants with higher risk for COVID-19 (based on age, gender, race / ethnicity, profession, comorbidity) living in, or going to, locations with high SARS-CoV-2 activity, after administration of two doses of study vaccine.
Study URL:Back to listing